Vaccines for Guillain-Barré Syndrome
Creative Biolabs provides global customers with the best solutions in the field of autoimmune disease vaccine development. We have successfully accomplished many projects in autoimmune disease vaccine development services for Guillain-Barré syndrome. With our extensive experience and advanced platform, we are confident in offering the best vaccine development services for Guillain-Barré syndrome.
Introduction of Guillain-Barré Syndrome
Guillain-Barré syndrome (GBS) is an autoimmune disease of the nervous system, which is accompanied by symmetric flaccid paralysis of the extremities, sensory abnormalities, and cranial nerve palsy. It is the most common and most severe acute or subacute paralytic neuropathy, with about 100,000 people worldwide suffer from this disease every year. This pathology is characterized by T-cell reactivity against the myelin of peripheral nerves, causing long-term paraparesis, a bedridden state and the need for respiratory assistance. Treatment with intravenous immunoglobulin or plasma exchange is the optimal management approach, alongside supportive care.
The Pathogen of Guillain-Barré Syndrome
Guillain-Barré syndrome is usually preceded by infection or other immune stimulation that induces abnormal autoimmune responses targeting peripheral nerves and their spinal roots. Molecular mimicry between microbes and nerve antigen is clearly the main driving force of the development of the disorder, at least in the case of Campylobacter jejuni infection. However, the interaction between microbial and host factors that determines if and how the immune response is shifted towards unwanted autoreactivity is still not well understood. In addition, genetic and environmental factors that influence an individual's susceptibility to disease are unclear.
Vaccines for Guillain-Barré Syndrome
GBS is an acute polyradiculoneuropathy with a variable clinical presentation. Accurate diagnostic criteria are essential for patient care and research, including clinical trials and vaccine studies. It is difficult to accurately diagnose at an early stage because of its diverse causes and clinical presentations, therefore, vaccines play an increasingly important role in the prevention of this disease. The animal model of GBS is Experimental Autoimmune Neuritis (EAN) which is caused by the antigenicity of a myelin protein expressed in the periphery, P2. The peptide vaccine consisting of a peptide complementary to the major immunogenic region of the P2 protein and keyhole limpet hemocyanin (KLH) can partially inhibit the occurrence of clinical diseases and is a potential method for preventing GBS.
Our Services for Guillain-Barré Syndrome Vaccine
With a variety of mature and comprehensive platforms and technologies for the evaluation and improvement of vaccine development, our platform is dedicated to providing the best solutions and protocols customized to vaccines development for GBS. Our service has the following characteristics:
- Help develop vaccines with the appropriate immune response
- Provide specialized vaccine development designs and solutions based on customer needs
- Evaluation and data analysis of the immune effects of candidate vaccine
Creative Biolabs is a leader in the field of vaccine development and has focused on vaccine development services for years. We have experienced experts and advanced platforms that are able to provide excellent vaccine services for autoimmune disease. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
